A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2023-04-25
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Nausea — outcome: UNKNOWN; onset 2023-06-28 (study day 45); relationship: not assessed
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-08-10 (study day 88); relationship: N
severe
assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-04 (study day 143); relationship: N
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-12 (study day 151); relationship: Y
Data queries
No data queries.